SGD can significantly change the mRNA expression of genes related to the BAs metabolic pathway, and improve dyslipidemia in PCOS rats by reshaping the gut microbiota structure and regulating the bile acid/FXR pathway. This evidence concerns the gene NR1H4 and specific granule deficiency.